CCR5-antagonists: Contribution of a new antiretroviral class to the management of HIV infection;Antagonistes du CCR5: Apport d'une nouvelle classe d'antirétroviraux dans la prise en charge de l'infection par le VIH

Medecine et Maladies Infectieuses

Volumn 40, Issue 5, 2010, Pages 245-255

  Poizot Martin, I ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

AIDS; CCR5; HIV; Maraviroc; R5 tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYTOCHROME P450 3A4; EFAVIRENZ; FOSAMPRENAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; TIPRANAVIR; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVIEW; UNSPECIFIED SIDE EFFECT; VIROGENESIS; VIRUS ENTRY; VIRUS LOAD; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; PHYSIOLOGY; VIRAL TROPISM;

ANTI-RETROVIRAL AGENTS; CYCLOHEXANES; HIV; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; TRIAZOLES; VIRAL TROPISM; CCR5 RECEPTOR ANTAGONISTS;

EID: 77952869069     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.03.007     Document Type: Review

References (53)

1. Mary-Krause M., Fichou J., Lanoy E., Lièvre L., Costagliola D. L'infection à VIH après 10 ans de traitements antirétroviraux actifs dans la base de données hospitalière française sur l'infection à VIH (ANRS CO4 FHDH). BEH 2007, 46-47:394-397. le Groupe d'épidémiologie clinique de l'ANRS CO4 FHD.
2. Yéni P. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Rapport 2008. Paris: Flammarion Médecine-Sciences; 2008, http://www.sante.gouv.fr/.
3. Moore R.D., Keruly J.C. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007, 44:441-446.
4. Poles M.A., Boscardin, Elliott J., Taing P., Fuerst M.M.P., McGowan I., et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006, 43:65-68.
5. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-1441.
6. Fätkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman A.I., Lampiris H., et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-1455.
7. Dumond J., Patterson K., Pecha A., Werner R., Andrews E., Damle B., et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue issue of HIV-negative women. J Acquir Immune Defic Syndr 2009, 51:546-553.
8. Walker D.K., Bowers S.J., Mitchell R.J., Potchoiba M.J., Schroeder C.M., Small H.F. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008, 38:1330-1339.
9. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
10. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
11. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998, 101:746-754.
12. Dolan M.J., Kulkarni H., Camargo J.F., He W., Smith A., Anaya J.M., et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007, 8:1324-1336.
13. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86367-86377.
14. de Roda Husman A.M., Koot M., Cornelissen M., Keet I.P., Brouwer M., Broersen S.M., et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997, 127:882-890.
15. Moore J.P., Doms R.W. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 2003, 100:10598-10602.
16. Westby M., van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005, 16:339-354.
17. Frange P., Galimand J., Goujard C., Deveau C., Ghosn J., Rouzioux C., et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009, 64:135-141.
18. Moyle G.J., Wildfire A., Mandalia S., Mayer H., Goodrich J., Whitcomb J., et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 19:866-872.
19. Wilkin T.J., Su Z., Kuritzkes D.R., Hughes M., Flexner C., Gross R., et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007, 44:591-595.
20. Brumme Z.L., Goodrich J., Mayer H.B., Brumme C.J., Henrick B.M., Wynhoven B., et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005, 192:466-474.
21. Coakley E, Benhamida J, Chappey C, Whitcomb J, Goodrich J, van der Ryst E, et al. An evaluation of tropism profiles and other characteristics among 3988 individuals screened from A4001026, A4001027 (MOTIVATE 1) and A4001028 (MOTIVATE 2) studies for maraviroc. In: Second International Workshop on Targeting HIV Entry. Boston, MA; October 20-21, 2006 (abstract 8).
22. Moore J.P., Kitchen S.G., Pugach P., Zack J.A. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111-126.
23. Richman D.D., Bozzette S.A. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
24. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
25. EPAR. European Medicines Agency CHMP assessment report for CELSENTRI®. 2007.
26. Nelson M, Fisher M, Gonzalez-Garcia J, Rockstroh J, Chambers R, Weinstein D, et al. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc (MVC) plus an optimized background therapy (OBT) versus placebo (PBO) plus OBT in the MOTIVATE 1 and 2 trials [abstract]. In: 17th International Aids Conference. Mexico; 2008 (abstract TUPE 0119).
27. Mayer H, van der Ryst E, Saag M, Clotet B, Fatkenheuer G, Clumeck N, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract]. In: 16th International AIDS Conference. Montreal, Canada; august 2006 (abstract THLB0215).
28. Stepanyuk O., Chiang T.S., Dever L.L., Paez S.L., Smith S.M., Perez G., et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009, 23:1911-1913.
29. Lelièvre J.D., Petit F., Perrin L., Mammano F., Arnoult D., Ameisen J.C., et al. The density of coreceptors at the surface of CD4+ T cells contributes to the extent of human immunodeficiency virus type 1 viral replication-mediated T cell death. AIDS Res Hum Retroviruses 2004, 20:1230-1243.
30. Ahuja S.K., Kulkarni H., Catano G., Agan B.K., Camargo J.F., He W., et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008, 14:413-420.
31. Vincent T., Portalès P., Baillat V., Eden A., Clot J., Reynes J., et al. The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 density. J Acquir Immune Defic Syndr 2006, 43:377-378.
32. Lin Y.L., Mettling C., Portales P., Reynes J., Clot J., Corbeau P. Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A 2002, 99:15590-15595.
33. Johnson M, Soriano V, Brockmeyer N, Winston A, Gellermann HJ, Caims V, et al. Early virological and immunological response is comparable for nevirapine and RTV-boosted atazanavir: an ARTEN sub-analysis. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009). San Francisco; September 12-15, 2009 (abstract H-924c).
34. Bennetto-Hood C., Johnson V.A., King J.R., Hoesley C.J., Acosta E.P. Novel methodology for antiretroviral quantitation in the female genital tract. HIV Clin Trials 2009, 10:193-199.
35. Dinoso J.B., Kim S.Y., Wiegand A.M., Palmer S.E., Gange S.J., Cranmer L., et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009, 106:9403-9408.
36. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS 2006, 20(5):641.
37. Gulick R.M., Su Z., Flexner C., Hughes M.D., Skolnik P.R., Wilkin T.J., et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007, 196:304-312.
38. Hardy WD, Gulick R, Mayer H, Fätkenheuer G, Nelson M, Heera J, et al. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-1: 96-week combined analysis of the Motivate 1 and 2 studies [abstract]. In: 9th International congress on drug therapy in HIV infection. Glasgow; November 2008 (abstract 425).
39. Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumecket N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study [abstract]. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 2007 (abstract WESS104).
40. Emmelkamp J.M., Rockstroh J.K. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 2007, 12:409-417.
41. Abel S., Russell D., Taylor-Worth R.J., Ridgway C.E., Muirhead G.J. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 2008, 65(Suppl 1):27-37.
42. Daar E.S., Kesler K.L., Petropoulos C.J., Huang W., Bates M., Lail A.E., et al. Hemophilia Growth and Development Study. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007, 45:643-649.
43. Trouplin V., Salvatori F., Cappello F., Obry V., Brelot A., Heveker N., et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001, 75:251-259.
44. Whitcomb J.M., Huang W., Fransen S., Limoli K., Toma J., Wrin T., et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007, 51:566-575.
45. Raymond S., Delobel P., Mavigner M., Cazabat M., Souyris C., Sandres-Sauné K., et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008, 22:F11-F16.
46. Trinh L, Han D, Huang W, Wrin T, Larson J, Kiss L, et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5 [abstract]. In: 17th International HIV drug resistance workshop. Sitges; June 2008 (abstract 118).
47. Morand-Joubert L, Flandre P, Soulié C, Charpentier C, Daugan M, Desbois D, et al. Higher detection of CXCR4 tropic virus by genotypic coreceptor analysis in peripheral blood mononuclear cells (PBMC) than in plasma. In: HIV 7th European Drug resistance Workshop. Stockholm; March 2009 (abstract 51).
48. Morand-Joubert L, Flandre P, Soulié C, Charpentier C, Desbois D, Ruffault A, et al. Evolution of coreceptor tropism and V3 loop resistance mutations in the blood cellular reservoir after introduction of Maraviroc. In: 18th International HIV Drug resistance Workshop. Fort-Myers; June 2009 (abstract 129).
49. Melby T. HIV coreceptor use in heavily treatment-experienced patients: does it take two to tangle?. Clin Infect Dis 2007, 44:596-598.
50. Huang W., Eshleman S.H., Toma J., Fransen S., Stawiski E., Paxinos E.E., et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007, 81:7885-7893.
51. Patel M.B., Hoffman N.G., Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol 2008, 82:903-916.
52. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361:212-228.
53. Menéndez-Arias L., Esté J.A. HIV-resistance to viral entry inhibitors. Curr Pharm Des 2004, 10:1845-1860.